AcquisitionOther
Novartis AG acquired Regulus Therapeutics
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Novartis AG -> Regulus Therapeutics · approximately $1.7 billion
Acquisition to bring farabursen, a first-in-class potential medicine for ADPKD patients, to market leveraging Novartis' global capabilities.
Open source record (SEC) ↗